LAVA Therapeutics N.V. today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.
The details of the poster presentation are as follows:
Abstract #: 153
Abstract Title: Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T cell engager (Gammabody™), in metastatic castration-resistant prostate cancer (mCRPC) patients
Session Title: Poster Session A: Prostate Cancer
Poster Board #: E13
Session Date: Thursday, February 16, 2023
Session Times: 11:30 AM-1:00 PM PT and 5:45 PM-6:45 PM PT
Presenter: Niven Mehra, Radboud University Medical Center, Department of Medical Oncology MD, PhD
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.
LAVA’sCautionaryNoteonForward-LookingStatements
This press release contains forward-looking statements, including in respect to the company’s anticipatedgrowth and clinical developments plans, and the timing and results of clinical trials. Words such as “anticipate,”“believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similarexpressions(aswellasotherwordsorexpressionsreferencingfutureevents,conditionsorcircumstances)are intended to identify forward-looking statements. These forward-looking statements are based onLAVA’s expectations and assumptions as of the date of this press release and are subject to various risksanduncertaintiesthatmaycauseactualresultstodiffermateriallyfromtheseforward-lookingstatements. Forward-looking statements contained in this press release include, but are not limited to,statements about the preclinical and clinical data, clinical development and scope of clinical trials, and the potentialuse of our product candidates to treat various tumor targets. Many factors, risks and uncertainties maycause differences between current expectations and actual results including, among other things, thetimingandresultsofourresearchanddevelopmentprogramsandpreclinicalandclinicaltrials,ourabilityto obtain regulatory approval for and commercialize our product candidates, our ability to leverage ourinitial programs to develop additional product candidates using our Gammabody™ platform, and thefailureofLAVA’scollaboratorstosupportoradvancecollaborationsorourproductcandidates. The COVID-19 pandemic may disrupt our business and that of the third parties on which we depend,including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing andsupply chain, or impairing employee productivity. In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new informationbecomes available.
CONTACTS
Investor Relations
ir@lavatherapeutics.com
Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com
